Damon Runyon News

January 18, 2023

The Damon Runyon Cancer Research Foundation has announced eight recipients of the 2023 Damon Runyon-Rachleff Innovation Award, established to support “high-risk, high-reward” ideas with the potential to significantly impact the prevention, diagnosis, or treatment of cancer. Five extraordinary early-career researchers will receive initial grants of $400,000 over two years, and each will have the opportunity to receive two additional years of funding (for a potential total of $800,000).

January 13, 2023

Small-cell lung cancer (SCLC), which accounts for about 15% of lung cancer diagnoses, is a relatively rare but aggressive disease. Most SCLC patients respond to chemotherapy at first, but nearly all experience disease recurrence, and at that point treatment options become scarce. Because SCLC is driven by mutations that knock out “tumor suppressor” genes, rather than activate cancer driver genes, it has been difficult to treat with targeted therapies.

December 19, 2022

Myeloproliferative neoplasms (MPNs) are cancers that arise when a mutated blood stem cell begins to produce too many mature blood cells. A number of mutations can drive MPNs, and studies have demonstrated that different mutations result in different clinical outcomes.


December 12, 2022

Thanks to research by Damon Runyon scientists Melody Smith, MD, Elizabeth Hughes, PhD, and many others, the impact of gut bacteria on cancer immunotherapy response is becoming clearer. The presence of certain bacteria, such as Akkermansia muciniphila, in patient stool samples has been shown to correlate with better response to immunotherapies, suggesting that these microbes play a pivotal role in stimulating immune response.

December 8, 2022

Pancreatic cancers are notoriously resistant to treatment, in part because more than 90% of tumors are driven by mutations in the notorious KRAS gene. Once considered an “undruggable” cancer target, the first KRAS inhibitors are now making their way into clinics, but so far therapies have only been approved for the treatment of lung cancer.

November 14, 2022

We are delighted to announce that former Damon Runyon-Illini 4000 Fellow Daniel J. Blair, PhD, of St. Jude Children’s Research Hospital, has been named a 2022 STAT Wunderkind. This award, granted annually to “the best early-career researchers in health and medicine in North America,” recognizes Dr. Blair’s exceptional promise in the field of synthetic chemistry.

October 26, 2022

In 2018, the Foundation for the National Institutes of Health (FNIH) established the FNIH Trailblazer Prize for Clinician-Scientists to recognize “the outstanding contributions of early career clinician-scientists” whose research “translates basic scientific observations into new paradigm-shifting approaches for diagnosing, preventing, treating or curing disease.” 


October 21, 2022

Each year, the Damon Runyon-Jake Wetchler Award for Pediatric Innovation is given to a third-year Damon Runyon Fellow whose research has the greatest potential to impact the prevention, diagnosis, or treatment of pediatric cancer. This year, the award recognizes the work of Anand G. Patel, MD, PhD, a Damon Runyon-Sohn Pediatric Cancer Fellow at St. Jude Children's Research Hospital. As a physician-scientist, Dr. Patel both provides care for children with cancer and their families and investigates ways to improve their treatment options.


October 12, 2022

Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own immune cells are genetically engineered to target cancer cells, has revolutionized the treatment of certain blood cancers. Unfortunately, CAR T cell therapy is much less effective against solid tumors, such as pancreatic or skin cancer. Part of the problem in these cases is that the genetically altered T cells quickly become dysfunctional; even those that exhibit a strong anti-tumor response at first soon reach a state of exhaustion. At the University of California, Los Angeles, Damon Runyon Clinical Investigator Anusha Kalbasi, MD, and his colleagues are investigating how to make these T cells last longer to better treat melanoma and other deadly solid tumors. Recently, they had a breakthrough.


October 11, 2022

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, occurring primarily in patients with chronic liver damage, such as that caused by hepatitis B, hepatitis C, or long-term alcohol use. It is the third-highest cause of cancer mortality worldwide. Unfortunately, because HCC develops slowly and can be asymptomatic for years, patients are often diagnosed at an advanced stage.